Segall Bryant & Hamill LLC Buys 6,789 Shares of iRhythm Technologies, Inc. (NASDAQ:IRTC)

Segall Bryant & Hamill LLC increased its stake in iRhythm Technologies, Inc. (NASDAQ:IRTC) by 5.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 139,391 shares of the company’s stock after acquiring an additional 6,789 shares during the period. Segall Bryant & Hamill LLC owned about 0.45% of iRhythm Technologies worth $12,569,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Intech Investment Management LLC bought a new stake in iRhythm Technologies in the third quarter valued at approximately $702,000. Charles Schwab Investment Management Inc. raised its holdings in iRhythm Technologies by 1.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 255,703 shares of the company’s stock valued at $18,983,000 after buying an additional 4,173 shares during the last quarter. Algert Global LLC grew its holdings in iRhythm Technologies by 332.8% in the 3rd quarter. Algert Global LLC now owns 13,560 shares of the company’s stock worth $1,007,000 after acquiring an additional 10,427 shares during the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in shares of iRhythm Technologies in the third quarter valued at about $1,497,000. Finally, The Manufacturers Life Insurance Company raised its stake in shares of iRhythm Technologies by 7.3% during the third quarter. The Manufacturers Life Insurance Company now owns 196,423 shares of the company’s stock valued at $14,582,000 after acquiring an additional 13,377 shares during the last quarter.

Analyst Ratings Changes

IRTC has been the topic of a number of research analyst reports. Canaccord Genuity Group boosted their price target on iRhythm Technologies from $125.00 to $152.00 and gave the company a “buy” rating in a report on Monday, December 9th. Wells Fargo & Company upped their target price on iRhythm Technologies from $86.00 to $104.00 and gave the company an “equal weight” rating in a report on Friday, February 21st. Truist Financial lifted their price target on shares of iRhythm Technologies from $111.00 to $145.00 and gave the company a “buy” rating in a report on Friday, February 21st. Oppenheimer raised their target price on shares of iRhythm Technologies from $105.00 to $120.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 8th. Finally, Needham & Company LLC lifted their target price on shares of iRhythm Technologies from $125.00 to $138.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, iRhythm Technologies has an average rating of “Moderate Buy” and an average target price of $119.73.

iRhythm Technologies Stock Up 0.7 %

IRTC stock opened at $106.60 on Wednesday. The company has a quick ratio of 6.12, a current ratio of 6.27 and a debt-to-equity ratio of 9.00. The business has a 50 day moving average of $108.14 and a 200 day moving average of $89.47. iRhythm Technologies, Inc. has a twelve month low of $55.92 and a twelve month high of $128.52. The firm has a market cap of $3.35 billion, a PE ratio of -29.29 and a beta of 1.36.

iRhythm Technologies (NASDAQ:IRTC) last posted its quarterly earnings results on Thursday, February 20th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.30. The firm had revenue of $164.33 million during the quarter, compared to analyst estimates of $158.30 million. iRhythm Technologies had a negative return on equity of 118.83% and a negative net margin of 19.14%. On average, research analysts forecast that iRhythm Technologies, Inc. will post -1.98 EPS for the current fiscal year.

iRhythm Technologies Company Profile

iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.